Future perspectives: targeting fibroblast growth factor receptor 1 to enhance the efficacy of immunotherapy
Ilya Tsimafeyeu
Exploration of Targeted Anti-tumor Therapy ›› 2025, Vol. 6 ›› Issue (1) : 1002327
Fibroblast growth factor receptor 1 (FGFR1) plays a critical role in the progression of various cancers through its involvement in cell proliferation, survival, and differentiation. More recently, FGFR1 has been implicated in the mechanisms of immune evasion, particularly its role in resistance to immune checkpoint inhibitors (ICIs) such as pembrolizumab and nivolumab. Targeting FGFR1 with monoclonal antibodies and tyrosine kinase inhibitors has emerged as a promising therapeutic strategy to enhance ICI efficacy by altering the tumor microenvironment and countering immune suppression. Preclinical studies demonstrate that combining FGFR1 inhibitors, such as the novel monoclonal antibody OM-RCA-01, with ICIs significantly improves antitumor activity, enhancing T cell responses and cytokine production. This article explores the role of FGFR1 in cancer biology, its contribution to immunotherapy resistance, and the therapeutic potential of targeting FGFR1 to enhance the efficacy of ICIs.
Fibroblast growth factor receptor 1 / anti-FGFR1 antibody / immune checkpoint inhibitors / resistance
| [1] |
|
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
|
| [18] |
Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, |
| [19] |
|
| [20] |
|
| [21] |
|
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, |
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
SenthilKumar G, Fisher MM, Skiba JH, Miller MC, Brennan SR, |
| [39] |
|
| [40] |
|
| [41] |
FDA approves pemigatinib for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement [Internet]. U.S. Food and Drug Administration; [cited 2024 Sep 9]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pemigatinib-relapsed-or-refractory-myeloidlymphoid-neoplasms-fgfr1-rearrangement |
| [42] |
|
| [43] |
|
| [44] |
Bahleda R, Meric-Bernstam F, Goyal L, Tran B, He Y, Yamamiya I, |
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
Salazar L, Kashiwada T, Krejci P, Meyer AN, Casale M, Hallowell M, |
| [52] |
Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, |
| [53] |
|
| [54] |
|
| [55] |
|
| [56] |
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102) [Internet]. [cited 2024 Sep 9]. Available from: https://classic.clinicaltrials.gov/ct2/show/NCT05111626 |
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
Tang T, Huang X, Zhang G, Hong Z, Bai X, |
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
/
| 〈 |
|
〉 |